trial

Glycine and D-Cycloserine in Schizophrenia

NCTId NCT00000372
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Withdrawn
Enrollment 0 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2005-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
1998-03
Primary completion
2005-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
d-cycloserineglycineClozapine

Sponsors

Massachusetts General HospitalLead Sponsor

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

1 total
Boston, United States

Linked catalysts

1
Glycine and D-Cycloserine in Schizophrenia — primary completion2005-11

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE3
Primary Completion Date
2005-11
Status
WITHDRAWN
relationships
The graph out of here
drug
d-cycloserine
drug
glycine
drug
Clozapine
drug
lead_sponsor
Massachusetts General Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person